A new—and costly—category of weight loss drugs has burst into the market, targeting the nearly 40% of the world’s population who are overweight or obese. Considered by some experts to be a game changer in obesity, GLP-1 (glucagon-like peptide-1) receptor agonists are in such high demand that some people with diabetes (the original indication) are […]